Anna Chacon, MD
Dermatology · Coral Gables
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 9
- Since medical school
- 14 years
- Graduated 2012
Offices
9 locations · Peacehealth · Lake County Tribal Health Consortium Inc · Chacon Bnk PC · Telemedicine Group PC · Compass Dermatopathology Inc · Vitalmd Group Holding LLC · Centennial Housing and Community Services Corporation
Looking this up.
Hospitals listed: Ketchikan Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Chacon’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Florida ME127579Medical Doctor · since 2016 · expires 2028-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Dermatology
Education
- Warren Alpert Medical School of Brown University · MD2008–2012Medical school
Residency and fellowship
- LAC + USC Medical Center, DERMATOLOGYLos Angeles, CA · 2016–2018
- University of Maryland Medical Center, DermatologyBALTIMORE, MD · 2014–2016
- Orlando Health - Surgery Internship, SurgeryORLANDO, FL · 2013–2014
What else the board holds
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peacehealth Ketchikan Medical CenterKetchikan, AKCritical Access Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Peacehealth, which runs 10 hospitals in 3 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Peacehealth Ketchikan Medical Center
Behind the star rating — Deaths: 0 better, 3 the same, 0 worse of 3 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for heart failure patientsComplications and deaths | 10.2 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.9 · 65 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 182 cases | None | Jul 2024 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 38 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 13.3 · 51 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.7 · 77 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.8 (3.7 to 8.8) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11 (7.5 to 15.7) · 26 cases | No different | Jan 2024 – Dec 2024 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.4 to 17.3) · 166 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 42 cases | No different | Jan 2024 – Dec 2024 |
What patients said (136 patients answered, 22% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 5 |
| Recommend hospital | 5 |
| Room was "always" clean | 81% |
| Nurses "always" communicated well | 83% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 67% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 90% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 80% |
| Nurses "always" listened carefully | 81% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 76% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 56% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$8,474
Medicare paid this office $8,474 for 31 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| New patient visit (15+ min) | 12 | $308 | $26 |
Procedures Medicare counted
| Removal of nail tissue | 1-10 | None |
| Removal of skin lesions | 26 | More than 67% of doctors who do this |
| Removal of tissue | 1-10 | None |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 1-10 | None |
Procedures year by year
| Procedure | 2018 | 2019 | 2020 | 2021 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 42 | 242 | 116 | 107 | – | – |
| Destruction of precancer skin growth, 1 growth | 41 | 207 | 140 | 99 | – | – |
| Destruction of skin growth, 1-14 growths | 20 | 112 | 79 | 84 | – | – |
| Biopsy of related skin growth, first growth | – | 82 | 67 | 35 | – | – |
| Biopsy of related skin growth, each additional growth | – | 26 | 31 | 14 | – | – |
| Injection into skin growth, 1-7 growths | – | 33 | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
31 Original Medicare patients in 2024. Average age 72 · Women 42% · Health risk score 1.05. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 61%.
The office billed $13,982, Medicare allowed $11,504 and paid $8,474; for 158 services of 20 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 31 | 158 | 72 | 1.05 | $13,982 | $8,474 |
| 2023 | 18 | 20 | 73 | 0.97 | $5,764 | $1,261 |
| 2021 | 326 | 808 | 74 | 1.43 | $199,431 | $61,724 |
| 2020 | 400 | 1,251 | 74 | 1.59 | $256,764 | $77,065 |
| 2019 | 423 | 1,548 | 73 | 1.25 | $361,340 | $103,131 |
| 2018 | 115 | 256 | 72 | 1.16 | $51,483 | $16,056 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| New patient visit (30+ min) | 12 | $794 | $66 |
2021: 11 services
| Return visit (30+ min) | 180 | $20,212 | $94 |
| New patient visit (45+ min) | 87 | $10,934 | $126 |
| Destruction of skin growth, 1-14 growths | 80 | $7,127 | $85 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 18 | $5,615 | None |
| Destruction of precancer skin growth, 1 growth | 88 | $4,631 | $47 |
| Application of light by qualified health care professional to destroy precancer skin growth | 19 | $3,173 | $167 |
| Biopsy of related skin growth, first growth | 34 | $2,816 | $80 |
| New patient visit (30+ min) | 36 | $1,866 | $52 |
| Short return visit (20+ min) | 26 | $1,330 | $51 |
| Biopsy of related skin growth, each additional growth | 12 | $566 | $40 |
| Destruction of precancer skin growth, 2-14 growths | 68 | $541 | $5 |
2020: 13 services
| Return visit (30+ min) | 211 | $24,209 | $79 |
| New patient visit (30+ min) | 175 | $13,548 | $77 |
| Destruction of skin growth, 1-14 growths | 73 | $6,927 | $88 |
| Short return visit (20+ min) | 79 | $6,811 | $61 |
| Destruction of precancer skin growth, 1 growth | 109 | $6,348 | $45 |
| Biopsy of related skin growth, first growth | 60 | $4,983 | $74 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 14 | $4,833 | None |
| Application of light by qualified health care professional to destroy precancer skin growth | 12 | $2,219 | $158 |
| Biopsy of related skin growth, each additional growth | 22 | $1,381 | $45 |
| Telephone medical discussion with physician, 11-20 minutes | 19 | $1,260 | $63 |
| New patient visit (15+ min) | 12 | $698 | $58 |
| Destruction of precancer skin growth, 2-14 growths | 86 | $534 | $5 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 16 | $131 | None |
2019: 12 services
| Return visit (30+ min) | 239 | $32,591 | $84 |
| New patient visit (30+ min) | 238 | $18,265 | $77 |
| Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | 32 | $14,243 | None |
| Destruction of skin growth, 1-14 growths | 93 | $9,833 | $88 |
| Destruction of precancer skin growth, 1 growth | 141 | $9,285 | $45 |
| Biopsy of related skin growth, first growth | 67 | $5,947 | $73 |
| Application of light to destroy precancer skin growth | 27 | $2,681 | $99 |
| Short return visit (20+ min) | 28 | $1,620 | $58 |
| Injection into skin growth, 1-7 growths | 20 | $1,362 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 131 | $1,118 | $5 |
| Biopsy of related skin growth, each additional growth | 21 | $989 | $38 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 23 | $91 | None |
2018: 7 services
| New patient visit (30+ min) | 70 | $6,088 | $87 |
| Return visit (30+ min) | 30 | $2,601 | $87 |
| Destruction of precancer skin growth, 1 growth | 38 | $1,964 | $48 |
| Destruction of skin growth, 1-14 growths | 20 | $1,759 | $88 |
| Biopsy of single growth of skin and/or tissue | 13 | $1,098 | $84 |
| Short return visit (20+ min) | 17 | $1,021 | $60 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $189 | $4 |
Medicaid work
$27,923 in 2024
Medicaid paid $27,923 for 323 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 283 | $25,724 |
| New patient visit (30+ min) | 19 | $2,095 |
| Telehealth transmission, per minute, professional services bill separately | 21 | $104 |
| 2024 | 323 | 3 | 29 | $27,923 |
| 2023 | 126 | 2 | 30 | $7,979 |
| 2022 | 43 | 1 | 27 | $2,684 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 113 | $6,809 |
| Interprofessional telephone/Internet/electronic health record assessment and management service provided by a consultative physician or other qualified health care professional, including a written report to the patient's treating/requesting physician or other qualified health care professional, 5 minutes or more of medical consultative time | 13 | $1,170 |
2022
| Return visit (30+ min) | 43 | $2,684 |
Drugs they prescribed that Part D paid
$146,271
Pharmacies billed $146,271 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 822) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
761 generic and fewer than 11 brand-name prescriptions · $146,271 in drug cost · 131 antibiotic prescriptions to 84 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Mounjaro | 13 | $15,117 | $1,163 |
| Clobetasol Propionate | 39 | $2,320 | $59 |
| Tretinoin | 17 | $1,262 | $74 |
| Ketoconazole | 83 | $1,049 | $13 |
| Minoxidil | 49 | $889 | $18 |
See all 23 drugs
| Mounjaro | 13 | $15,117 | $1,163 |
| Clobetasol Propionate | 39 | $2,320 | $59 |
| Tretinoin | 17 | $1,262 | $74 |
| Ketoconazole | 83 | $1,049 | $13 |
| Minoxidil | 49 | $889 | $18 |
| Fluorouracil | 11 | $619 | $56 |
| Triamcinolone Acetonide | 70 | $596 | $9 |
| Doxycycline Monohydrate | 28 | $555 | $20 |
| Spironolactone | 14 | $377 | $27 |
| Methotrexate | 13 | $250 | $19 |
| Hydroxyzine | 23 | $215 | $9 |
| Cephalexin | 15 | $172 | $11 |
| Methylprednisolone | 19 | $118 | $6 |
| Mupirocin | 17 | $102 | $6 |
| Amoxicillin-Clavulanate Potass | 12 | $102 | $8 |
| Amoxicillin | 23 | $98 | $4 |
| Azithromycin | 18 | $95 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $90 | $7 |
| Prednisone | 39 | $87 | $2 |
| Hydrocortisone | 24 | $84 | $3 |
| Lisinopril | 17 | $84 | $5 |
| Venlafaxine Hcl Er | 11 | $74 | $7 |
| Ondansetron | 13 | $64 | $5 |
Year by year
| 2024 | 822 | 273 | 0% (0) | None | $146,271 |
| 2023 | 1,054 | 419 | 0% (0) | 24% | $370,782 |
| 2022 | 1,287 | 683 | 0% (0) | 8% | $210,999 |
| 2021 | 1,440 | 495 | 0% (0) | None | $223,403 |
| 2020 | 1,490 | 455 | 0% (0) | 10% | $258,125 |
| 2019 | 1,594 | 456 | 0% (0) | None | $199,265 |
| 2018 | 324 | 143 | 0% (0) | 13% | $172,514 |
| 2017 | 113 | 32 | None | 12% | $30,362 |
| 2016 | 195 | 64 | 0% (0) | 15% | $48,213 |
| 2015 | 513 | 156 | 0% (0) | 16% | $118,916 |
| 2014 | 180 | 71 | 0% (0) | None | $31,460 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 24 drugs
| Mounjaro | 128 | $144,232 | $1,127 |
| Ozempic | 90 | $113,563 | $1,262 |
| Clobetasol Propionate | 38 | $2,898 | $76 |
| Doxycycline Monohydrate | 43 | $2,007 | $47 |
| Metronidazole | 27 | $1,869 | $69 |
| Ketoconazole | 79 | $1,471 | $19 |
| Clindamycin Phosphate | 38 | $1,363 | $36 |
| Spironolactone | 23 | $700 | $30 |
| Doxycycline Hyclate | 25 | $660 | $26 |
| Minoxidil | 25 | $432 | $17 |
| Paxlovid (Eua) | 42 | $420 | $10 |
| Triamcinolone Acetonide | 42 | $411 | $10 |
| Hydrocortisone | 43 | $311 | $7 |
| Amoxicillin-Clavulanate Potass | 15 | $283 | $19 |
| Cephalexin | 15 | $276 | $18 |
| Azithromycin | 41 | $255 | $6 |
| Amoxicillin | 29 | $207 | $7 |
| Ondansetron | 12 | $195 | $16 |
| Hydroxyzine | 19 | $193 | $10 |
| Methylprednisolone | 17 | $169 | $10 |
| Mupirocin | 15 | $148 | $10 |
| Prednisone | 27 | $69 | $3 |
| Lisinopril | 13 | $63 | $5 |
| Ciprofloxacin | 12 | $47 | $4 |
2022: 31 drugs
| Mounjaro | 57 | $61,913 | $1,086 |
| Ozempic | 12 | $11,373 | $948 |
| Doxycycline Monohydrate | 83 | $6,743 | $81 |
| Clobetasol Propionate | 38 | $2,934 | $77 |
| Clindamycin Phosphate | 41 | $2,283 | $56 |
| Paxlovid (Eua) | 185 | $1,919 | $10 |
| Ketoconazole | 94 | $1,849 | $20 |
| Metronidazole | 24 | $1,778 | $74 |
| Tretinoin | 12 | $1,232 | $103 |
| Fluocinolone Acetonide | 15 | $1,114 | $74 |
| Permethrin | 23 | $916 | $40 |
| Triamcinolone Acetonide | 98 | $880 | $9 |
| Azithromycin | 75 | $588 | $8 |
| Doxycycline Hyclate | 13 | $546 | $42 |
| Ivermectin | 15 | $535 | $36 |
| Fluconazole | 18 | $488 | $27 |
| Cephalexin | 24 | $454 | $19 |
| Ciclopirox | 12 | $380 | $32 |
| Hydrocortisone | 54 | $344 | $6 |
| Amoxicillin-Clavulanate Potass | 23 | $331 | $14 |
| Nitrofurantoin Mono-Macro | 14 | $261 | $19 |
| Spironolactone | 22 | $253 | $11 |
| Amoxicillin | 47 | $245 | $5 |
| Mupirocin | 18 | $207 | $12 |
| Terbinafine | 14 | $197 | $14 |
| Minoxidil | 11 | $190 | $17 |
| Ciprofloxacin | 18 | $176 | $10 |
| Methylprednisolone | 21 | $156 | $7 |
| Hydroxyzine | 12 | $128 | $11 |
| Sulfamethoxazole-Trimethoprim | 18 | $85 | $5 |
| Prednisone | 20 | $59 | $3 |
2021: 18 drugs
| Dupixent | 23 | $73,385 | $3,191 |
| Clobetasol Propionate | 170 | $10,909 | $64 |
| Ketoconazole | 284 | $5,775 | $20 |
| Fluorouracil | 43 | $4,793 | $111 |
| Doxycycline Monohydrate | 81 | $4,362 | $54 |
| Tretinoin | 40 | $3,671 | $92 |
| Clindamycin Phosphate | 33 | $2,688 | $81 |
| Triamcinolone Acetonide | 275 | $2,652 | $10 |
| Metronidazole | 16 | $2,040 | $128 |
| Betamethasone Diprop Augmented | 18 | $1,625 | $90 |
| Fluocinolone Acetonide | 13 | $1,065 | $82 |
| Ciclopirox | 33 | $972 | $29 |
| Hydroxyzine | 64 | $838 | $13 |
| Hydrocortisone | 99 | $566 | $6 |
| Ammonium Lactate | 16 | $337 | $21 |
| Mupirocin | 37 | $284 | $8 |
| Spironolactone | 29 | $202 | $7 |
| Terbinafine | 11 | $73 | $7 |
2020: 22 drugs
| Humira(Cf) | 20 | $114,329 | $5,716 |
| Dupixent | 23 | $72,255 | $3,142 |
| Fluorouracil | 100 | $10,881 | $109 |
| Clobetasol Propionate | 121 | $8,580 | $71 |
| Ketoconazole | 335 | $8,114 | $24 |
| Jublia | 12 | $7,611 | $634 |
| Betamethasone Diprop Augmented | 43 | $5,234 | $122 |
| Triamcinolone Acetonide | 265 | $3,606 | $14 |
| Doxycycline Monohydrate | 52 | $2,741 | $53 |
| Clindamycin Phosphate | 25 | $2,023 | $81 |
| Metronidazole | 14 | $1,840 | $131 |
| Tretinoin | 16 | $1,578 | $99 |
| Ciclopirox | 38 | $1,547 | $41 |
| Fluocinonide | 17 | $1,439 | $85 |
| Hydroxyzine | 57 | $996 | $17 |
| Valacyclovir | 25 | $715 | $29 |
| Mycophenolate Mofetil | 11 | $671 | $61 |
| Hydrocortisone | 95 | $511 | $5 |
| Spironolactone | 24 | $372 | $15 |
| Mupirocin | 31 | $241 | $8 |
| Terbinafine | 19 | $182 | $10 |
| Cephalexin | 11 | $133 | $12 |
2019: 19 drugs
| Clobetasol Propionate | 146 | $12,879 | $88 |
| Fluorouracil | 89 | $10,457 | $117 |
| Ketoconazole | 324 | $9,626 | $30 |
| Doxycycline Monohydrate | 84 | $4,600 | $55 |
| Triamcinolone Acetonide | 287 | $4,139 | $14 |
| Betamethasone Diprop Augmented | 33 | $3,150 | $95 |
| Metronidazole | 18 | $2,421 | $135 |
| Clindamycin Phosphate | 31 | $2,327 | $75 |
| Fluocinonide | 28 | $1,545 | $55 |
| Ciclopirox | 44 | $1,544 | $35 |
| Hydroxyzine | 48 | $922 | $19 |
| Ciprofloxacin | 11 | $843 | $77 |
| Mupirocin | 56 | $540 | $10 |
| Hydrocortisone | 105 | $487 | $5 |
| Valacyclovir | 18 | $418 | $23 |
| Terbinafine | 26 | $337 | $13 |
| Doxepin | 12 | $323 | $27 |
| Spironolactone | 15 | $186 | $12 |
| Cephalexin | 14 | $134 | $10 |
2018: 5 drugs
| Calcipotriene | 19 | $3,068 | $161 |
| Clobetasol Propionate | 32 | $2,555 | $80 |
| Ketoconazole | 38 | $1,291 | $34 |
| Triamcinolone Acetonide | 62 | $898 | $14 |
| Hydrocortisone | 34 | $205 | $6 |
2017: 4 drugs
| Clobetasol Propionate | 12 | $1,784 | $149 |
| Triamcinolone Acetonide | 13 | $299 | $23 |
| Ketoconazole | 15 | $198 | $13 |
| Hydrocortisone | 12 | $70 | $6 |
2016: 4 drugs
| Clobetasol Propionate | 36 | $11,410 | $317 |
| Triamcinolone Acetonide | 23 | $549 | $24 |
| Ketoconazole | 14 | $208 | $15 |
| Hydroxyzine | 14 | $91 | $7 |
2015: 9 drugs
| Clobetasol Propionate | 74 | $17,669 | $239 |
| Desonide | 36 | $4,792 | $133 |
| Fluocinonide | 21 | $2,271 | $108 |
| Fluocinolone Acetonide | 12 | $2,186 | $182 |
| Ketoconazole | 69 | $1,568 | $23 |
| Triamcinolone Acetonide | 65 | $1,227 | $19 |
| Hydroxyzine | 42 | $479 | $11 |
| Ammonium Lactate | 24 | $410 | $17 |
| Mupirocin | 17 | $351 | $21 |
2014: 5 drugs
| Clobetasol Propionate | 27 | $6,100 | $226 |
| Fluocinonide | 11 | $1,992 | $181 |
| Ketoconazole | 23 | $560 | $24 |
| Triamcinolone Acetonide | 18 | $394 | $22 |
| Hydroxyzine | 13 | $121 | $9 |
Money from drug and device companies
$2,238 in 2025
| 2025 | 4 | 4 | $1,875 | $2,238 |
| 2024 | 3 | 4 | None | $132 |
| 2023 | 4 | 4 | None | $118 |
| 2022 | 6 | 12 | $800 | $1,155 |
| 2021 | 8 | 21 | $512 | $1,002 |
| 2020 | 9 | 18 | None | $311 |
| 2019 | 13 | 41 | $887 | $3,097 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Eli Lilly and | Olumiant | $1,875 | 1 payment
|
| Organon | Vtama | $186 | 1 payment
|
| Amgen | Otezla | $150 | 1 payment
|
| Abbvie | Botox | $27 | 1 payment
|
See all 4 published payments
| Eli Lilly and | Consulting · 2025-12-11 | Olumiant | $1,875 |
| Abbvie | Meals · 2025-06-03 | Botox | $27 |
| Amgen | Meals · 2025-03-19 | Otezla | $150 |
| Organon | Meals · 2025-01-18 | Vtama | $186 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $132
| Janssen Scientific Affairs | Tremfya | $88 | 2 payments
|
| Verrica Pharmaceuticals | Ycanth | $25 | 1 payment
|
| Dermavant Sciences | Vtama | $19 | 1 payment
|
2023: $118
| Incyte | Opzelura | $43 | 1 payment
|
| Janssen Scientific Affairs | Tremfya | $33 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $23 | 1 payment
|
| Arcutis Biotherapeutics | None | $19 | 1 payment
|
2022: $1,155
| Teladoc Health | None | $800 | 1 payment
|
| ViiV Healthcare | Cabenuva | $137 | 5 payments
|
| Galderma Laboratories L.P. | None | $129 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $54 | 1 payment
|
| Pfizer | Eucrisa | $21 | 1 payment
|
| Journey Medical | Qbrexza | $15 | 1 payment
|
2021: $1,002
| Sentynl Therapeutics | None | $267 | 1 payment
|
| Genzyme | Dupixent | $245 | 1 payment
|
| ViiV Healthcare | Cabenuva | $217 | 11 payments
|
| Amgen | Otezla | $79 | 2 payments
|
| Janssen Biotech | Tremfya | $61 | 3 payments
|
| EPI Health | Cloderm | $59 | 1 payment
|
| Pfizer | Eucrisa | $46 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $28 | 1 payment
|
2020: $311
| Genzyme | Dupixent | $67 | 3 payments
|
| Amgen | Otezla | $49 | 3 payments
|
| Sun Pharmaceutical Industries | Blu-U | $48 | 3 payments
|
| ViiV Healthcare | Dovato | $42 | 2 payments
|
| Regeneron Healthcare Solutions | Dupixent | $37 | 2 payments
|
| Genentech USA | Erivedge | $23 | 2 payments
|
| Pfizer | Eucrisa | $16 | 1 payment
|
| Merz North America | None | $15 | 1 payment
|
| Janssen Biotech | Tremfya | $13 | 1 payment
|
2019: $3,097
| Allergan | None | $984 | 2 payments
|
| Celgene | Otezla | $383 | 5 payments
|
| AbbVie | Humira | $364 | 6 payments
|
| Genzyme | Dupixent | $339 | 3 payments
|
| Sun Pharmaceutical Industries | Ilumya | $309 | 4 payments
|
| Regeneron Healthcare Solutions | Dupixent | $235 | 4 payments
|
| Galderma Laboratories L.P. | Soolantra | $199 | 2 payments
|
| Lilly USA | Taltz | $93 | 2 payments
|
| DUSA Pharmaceuticals | Blu-U | $69 | 5 payments
|
| Janssen Biotech | Tremfya | $37 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $37 | 2 payments
|
| ViiV Healthcare | Dovato | $36 | 2 payments
|
| LEO Pharma | Enstilar | $11 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study With A Doubleblind 52week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo · 2025 | Their institution | $148,294 |
| PFIZER INC. · A Phase 3 Randomized Doubleblind 52week Placebocontrolled Multicenter Study With A Doubleblind 52week Extension Period With Randomized Dose Updose Down Titration Investigating the Efficacy Safety and Tolerability of Ritlecitinib in Adult Participants With Nonsegmental Vitiligo · 2024 | Their institution | $35,975 |
| SANOFI PASTEUR INC. · A Phase I/II, Randomized, Placebo-Controlled, Multi-Arm, Dose-Finding Study To Evaluate the Safety, Efficacy and Immunogenicity of An Acne Mrna Vaccine Candidate in Adults With Moderate To Severe Acne 18 To 45 Years of Age · 2025 | Their institution | $31,741 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 98.4 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1073950689
- Licence
- FL ME125579, FL ME127579Florida ME127579: Active
- Group
- Peacehealth · Lake County Tribal Health Consortium Inc · Chacon Bnk PC · Telemedicine Group PC · Compass Dermatopathology Inc · Vitalmd Group Holding LLC · Centennial Housing and Community Services Corporation
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); General practice (208D00000X)
- Mailing address
- 135 Madeira Ave, Coral Gables, FL, 33134
- NPI first listed
- 2013-05-23
- NPI last updated
- 2026-09-10
- NPI record certified
- 2026-09-10
This is when the NPI record was last certified, not a medical board exam.